# New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response.

*biotech · news · 2026-04-17 · The Manila Times*

## Key points

- EVX-01 personalized vaccine triggered tumor-specific immune responses in 86% of selected targets.
- This 86% success rate is significantly higher than previously reported for other vaccine target identification methods.
- Durable vaccine-specific immune responses persisted for two years after EVX-01 administration in phase 2 data.
- AI-Immunology™ prediction scores positively correlate with the magnitude of measured immune responses.
- The trial in advanced melanoma showed a 75% Objective Response Rate, with three-year data expected in late 2026.

**Companies:** Merck & Co., Inc., Evaxion A/S
**Countries:** Denmark, USA

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/18/tmt-newswire/globenewswire/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial/2323041)

---

Canonical: https://newsio.io/n/50b870d8-5335-47ce-86fb-bd992822abda/new-phase-2-data-from-personalized-cancer-vaccine-evx-01-demonstrates-a-record-h
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works